Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® MR) in Healthy Participants under Fed Conditions.
S005190-206
Phase 1 other active
Quick answer
Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® MR) in Healthy Participants under Fed Conditions. for No medical condicion. is a Phase 1 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- No medical condicion.
- Phase
- Phase 1
- Modality
- other
- Status
- active